Form 4: Ginkgo Bioworks CFO Mark Dmytruk Reports Acquisition of Restricted Stock Units

Mark Dmytruk, CFO of Ginkgo Bioworks Holdings, Inc., reported the acquisition of restricted stock units (RSUs) on March 6, 2025.

Summary

• On March 6, 2025, Mark E. Dmytruk, the Chief Financial Officer of Ginkgo Bioworks Holdings, Inc., reported acquiring 4,245 Restricted Stock Units (RSUs).
• These RSUs represent a contingent right to receive shares of the company's Class A Common Stock.
• The RSUs vest in four equal installments: 25% on April 16, 2025, 25% on July 16, 2025, 25% on October 16, 2025, and the final 25% on January 16, 2026.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing related to executive compensation. The acquisition of RSUs could be interpreted as a slightly positive signal, but it's not a major event.

Positives

• The acquisition of RSUs by the CFO could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This filing is a routine disclosure related to executive compensation and is common for publicly traded companies. It provides transparency into the equity-based compensation of key executives.

Comparison to Industry Standards

• Equity compensation, such as RSUs, is a standard practice in the biotechnology industry to align executive interests with shareholder value.
• Companies like Amyris and Zymergen (before its acquisition) also utilized RSUs as part of their executive compensation packages.
• The vesting schedule of the RSUs (quarterly over a year) is fairly typical.

Stakeholder Impact

• The acquisition of RSUs by the CFO could have a minor positive impact on shareholder sentiment, as it aligns the executive's interests with those of the shareholders.

Key Dates